Tandem Diabetes Care Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
20analysts covering
FY Revenue (est.)
$1.1Bnext fiscal year
FY EPS (est.)
-$0.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Worldwide Pump Shipments Quarterly29KTarget: Double-digit growth for FY 2026
Worldwide Sales Quarterly247.2MTarget: 1065000000 to 1085000000
Gross Margin Quarterly55.0%Target: 56 to 57%
Adjusted EBITDA Margin Quarterly1.0%Target: 5 to 6%
Watch Items
- U.S. Pay-As-You-Go (Pay/Go) Model TransitionTrigger: Slower near-term revenue recognition and gross margin headwinds in 2026Action: Monitor quarterly U.S. pump shipment growth versus recognized GAAP revenue to assess underlying demand and transition velocity.
- Pharmacy Channel ShiftTrigger: Proportion of recurring supply sales moving through the pharmacy channelAction: Track gross margin expansion and cash flow predictability as high-margin recurring supply sales shift to premium-priced pharmacy channels.
- Mobi Tubeless FDA 510(k) SubmissionTrigger: Submission planned for Q2 2026Action: Verify regulatory filing timeline and subsequent FDA clearance to evaluate competitive positioning against tubeless alternatives.
Research as of 20 Jun 2026